{"id":483182,"date":"2020-05-07T22:28:01","date_gmt":"2020-05-07T22:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483182"},"modified":"2020-05-07T22:28:01","modified_gmt":"2020-05-07T22:28:01","slug":"benign-prostatic-hyperplasia-bph-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-pipeline-insight-2020_483182.html","title":{"rendered":"Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588851367.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588851367.jpeg\" alt=\"Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Benign prostatic hyperplasia (BPH) market. A detailed picture of the Benign prostatic hyperplasia (BPH) pipeline landscape is provided, which includes the disease overview and Benign prostatic hyperplasia (BPH) treatment guidelines.<\/div>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&#8220;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/benign-prostatic-hyperplasia-bph-pipeline-insight\" target=\"_blank\"><strong>Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020<\/strong><\/a>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;market. A detailed picture of the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;treatment guidelines.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;commercial assessment and clinical assessment of the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/a68f008b0ae533d55e0c74ff221b05a1.jpg\" alt=\"\" \/><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Benign prostatic hyperplasia (BPH)&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li class=\"ql-align-justify\">It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Benign prostatic hyperplasia (BPH)&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li class=\"ql-align-justify\">Detailed&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Benign prostatic hyperplasia (BPH).<\/li>\n<\/ul>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Report highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;Benign prostatic hyperplasia (BPH).&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">In the coming years, the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li class=\"ql-align-justify\">The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li class=\"ql-align-justify\">A detailed portfolio of major pharma players who are involved in fueling the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;treatment market. Several potential therapies for&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;Benign prostatic hyperplasia (BPH)&nbsp;market size in the coming years.&nbsp;&nbsp;<\/li>\n<li class=\"ql-align-justify\">Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;Benign prostatic hyperplasia (BPH)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-pipeline-insight\" target=\"_blank\"><strong>Request for sample pages:&nbsp;https:\/\/www.delveinsight.com\/sample-request\/benign-prostatic-hyperplasia-bph-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p class=\"MsoNormal\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; text-align: justify;\"><strong>1. Report Introduction<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>2. Benign prostatic hyperplasia (BPH)&nbsp;<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.1. Overview<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.2. History&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.3. Benign prostatic hyperplasia (BPH) Symptoms<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.4. Causes<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.5.Pathophysiology<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.6. Benign prostatic hyperplasia (BPH) Diagnosis&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>3. Benign prostatic hyperplasia (BPH)&nbsp;Current Treatment Patterns<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">3.1. Benign prostatic hyperplasia (BPH) Treatment Guidelines<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>4. Benign prostatic hyperplasia (BPH)&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.1. Benign prostatic hyperplasia (BPH)&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.2. Benign prostatic hyperplasia (BPH)&nbsp;Collaboration Deals<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">4.1.2.3. Benign prostatic hyperplasia (BPH)&nbsp;Acquisition Analysis<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>5. Therapeutic Assessment<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>6. Benign prostatic hyperplasia (BPH) Late Stage Products (Phase-III)<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>7. Benign prostatic hyperplasia (BPH) Mid Stage Products (Phase-II)<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>8. Early Stage Products (Phase-I)<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>9. Pre-clinical Products and Discovery Stage Products<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>10. Inactive Products<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>11. Dormant Products<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>12. Benign prostatic hyperplasia (BPH) Discontinued Products<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>13. Benign prostatic hyperplasia (BPH)&nbsp;Product Profiles<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.1. Product Description<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.2. Research and Development<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">Detailed information in the report?&nbsp;<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>14. Benign prostatic hyperplasia (BPH)&nbsp;Key Companies<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>15. Benign prostatic hyperplasia (BPH)&nbsp;Key Products<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>16. Dormant and Discontinued Products<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">16.1. Dormant Products<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>17. Benign prostatic hyperplasia (BPH)&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>18. Benign prostatic hyperplasia (BPH)&nbsp;Future Perspectives<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>19. Benign prostatic hyperplasia (BPH)&nbsp;Analyst Review&nbsp;&nbsp;<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\"><strong>21. Report Methodology<\/strong><\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">21.1. Secondary Research<\/p>\n<p class=\"gmail-ql-indent-1\" style=\"margin: 11.25pt 0in 0.0001pt; box-sizing: border-box; counter-reset: list-1 0 list-2 0 list-3 0 list-4 0 list-5 0 list-6 0 list-7 0 list-8 0 list-9 0; cursor: text; text-align: justify;\">21.2. Expert Panel Validation<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=benign-prostatic-hyperplasia-bph-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=benign-prostatic-hyperplasia-bph-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Benign prostatic hyperplasia (BPH) market. A detailed picture of the Benign prostatic hyperplasia &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-pipeline-insight-2020_483182.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,412,406,404],"tags":[],"class_list":["post-483182","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=483182"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/483182\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=483182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=483182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=483182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}